University of Utah Institutional Repository
Author Manuscript

1 **Cytosolic, but not mitochondrial, oxidative stress likely contributes to cardiac**
2 **hypertrophy resulting from cardiac specific GLUT4 deletion in mice.**
3
4 Yan Li, Adam R. Wende, Orathai Nunthakungwan, Yujia Huang, Eric Hu, Huifeng Jin,
5 Sihem Boudina, E. Dale Abel, Thunder Jalili
6
7 Corresponding author: Thunder Jalili, Ph.D.
8 250 S. 1850 E., Rm. 214
9 Salt Lake City, UT 84112
10 Tel 801-585-0399 Fax 801-585-3874
11 thunder.jalili@utah.edu
12
13 **Running title:** Cardiac specific GLUT4 deletion & oxidative stress
14 **Key Words:** ROS; mitochondria; cardiac hypertrophy; antioxidant; p67phox; GLUT4
15

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 **SUMMARY**

2 We hypothesized that oxidative stress may contribute to the development of hypertrophy
3 observed in mice with cardiac specific ablation of the insulin sensitive glucose
4 transporter 4 gene (GLUT4, $G4H^{-/-}$). Measurements of oxidized glutathione (GSSG) in
5 isolated mitochondria and whole heart homogenates were increased resulting in a lower
6 ratio of reduced glutathione (GSH) to GSSG. Membrane translocation of the $p67^{phox}$
7 subunit of cardiac NOX2 was markedly increased in $G4H^{-/-}$ mice, suggesting elevated
8 activity. To determine if oxidative stress was contributing to cardiac hypertrophy, 4-week
9 old Con and $G4H^{-/-}$ mice were treated with either tempol (T, 1mM, drinking water), a
10 whole cell antioxidant, or Mn(III)tetrakis(4-Benzoic acid) porphyrin chloride (MnTBAP, 10
11 mg/kg, ip), a mitochondrial targeted antioxidant, for 28d. Tempol attenuated cardiac
12 hypertrophy in $G4H^{-/-}$ mice (heart:tibia, Con 6.82±0.35, $G4H^{-/-}$ 8.83±0.34, Con+T
13 6.82±0.46, $G4H^{-/-}$+T 7.57±0.3), without changing GSH:GSSG, GPX4, or membrane
14 translocation of the $p67^{phox}$. Tempol did not modify phosphorylation of glycogen
15 synthase kinase (GSK) 3β or thioredoxin-2. In contrast, MnTBAP lowered mitochondrial
16 GSSG, improved GSH:GSSG, but did not prevent hypertrophy; indicating that
17 mitochondrial oxidative stress may not be critical for hypertrophy in this model. The
18 ability of tempol to attenuate cardiac hypertrophy suggests that a cytosolic source of
19 reactive oxygen species, likely NOX2, may contribute to the hypertrophic phenotype in
20 $G4H^{-/-}$ mice.

21

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 **INTRODUCTION**

2 Epidemiological and clinical studies report that diabetes is associated with
3 cardiac hypertrophy after adjusting for underlying coronary artery disease, ischemia or
4 hypertension [1-3]. Cardiac hypertrophy alone is an independent risk factor for
5 cardiovascular morbidity and mortality [4]. One commonly reported feature of the
6 diabetic heart is an increase in reactive oxidative species (ROS) [5-7]. Major sources of
7 ROS in the heart are NADPH oxidase and/or mitochondrial oxidative phosphorylation [8].
8 ROS are routinely removed by cellular antioxidants including superoxide dismutase
9 (SOD, consisting of two isoforms; a mitochondrial Mn-SOD and cytosolic Cu-Zn-SOD),
10 catalase, and glutathione peroxidase [8]. The characteristic increase in fatty acid β-
11 oxidation (FAO) in diabetes coupled with increased cellular oxygen demand and
12 mitochondrial dysfunction [9] increases the potential for ROS generation. Oxidative
13 stress has been reported to play a critical role in cardiac hypertrophy [10, 11]. Similarly,
14 impairment of endogenous antioxidant defenses through inhibition of thioredoxin results
15 in cardiac hypertrophy [12], while the loss of superoxide dismutase (SOD) exacerbates
16 hypertrophy in response to pressure overload [13].

17 We previously established a mouse model with cardiac specific deletion of the
18 glucose transporter 4 gene (GLUT4, $G4H^{-/-}$) to study the effect of impaired cardiac
19 glucose uptake on the ensuing cardiac phenotype [14]. Initial characterization revealed
20 that cardiomyocyte loss of both GLUT4 mRNA and protein resulted in moderate cardiac
21 hypertrophy without fibrosis [14]. This change in individual cardiomyocyte size develops
22 by eight weeks of age in the absence of hyperinsulinemia, hyperglycemia or changes in
23 serum concentrations of fatty acid, lactate, amino acids or ketones [14].

24 A recent study using an independently-generated murine model of GLUT4
25 deletion in the heart, superimposed upon reduced GLUT4 expression in skeletal muscle

University of Utah Institutional Repository
Author Manuscript

and fat, suggested that oxidative stress plays a role in cardiac hypertrophy, as treating adult mice (~150 d old) with tempol (a membrane permeable antioxidant) reversed cardiac hypertrophy [15]. Although tempol treatment in this study was associated with reduced mRNAs of NOX1 and $gp91^{phox}$, measured NADPH Oxidase activities were not altered in GLUT4 deficient hearts prior to and after tempol treatment. Thus the precise source of ROS in GLUT4 deficient hearts is not well characterized and the potential role that mitochondrial oxidative stress may play in stimulating cardiac hypertrophy in these hearts is incompletely understood. Moreover, the role of oxidative stress in cardiac hypertrophy in GLUT4 deficient hearts that are not confounded by systemic insulin resistance or reduced expression of GLUT4 in other tissues remains to be clarified. The contribution of mitochondria to ROS generation may be important in $G4H^{-/-}$ mice given the alterations in substrate utilization and FAO previously observed in insulin resistant hearts. Therefore, we hypothesized that reducing mitochondrial oxidative stress would prevent the development of cardiac hypertrophy in $G4H^{-/-}$ mice. To test this hypothesis we first determined the degree to which young and adult $G4H^{-/-}$ mice have cardiac oxidative stress, and then compared the effects of treating mice with 2 unique antioxidants; tempol and Mn(III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP) on development of cardiac hypertrophy. Tempol is a whole cell antioxidant that has been shown to reduce markers of oxidative stress in membrane, cytosol, and mitochondrial compartments [16, 17], while MnTBAP is a mitochondrial-targeted superoxide 2 mimetic. We report here that $G4H^{-/-}$ mice show signs of mild oxidative stress, which likely stems from NOX2, a cytosolic source of reactive oxygen species (ROS). Furthermore, while treatment with the whole cell antioxidant tempol attenuates cardiac hypertrophy, the mitochondrial-targeted antioxidant, MnTBAP, does not.

UU IR Author Manuscript

UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 **RESULTS**

2 **Cardiac hypertrophy and markers of oxidative stress.**

3 Mixed gender cohorts were used for all studies. Body mass (g) and tibia lengths
4 were similar between groups (Table 1). In agreement with previous studies that have
5 characterized the cardiac phenotype of these G4H$^{-/-}$ mice [14, 18], heart mass was
6 increased and cardiac hypertrophy was present in G4H$^{-/-}$ mice compared to Con at 25
7 weeks of age but was not present at 5 weeks of age (Table 1). Multiple markers of
8 oxidative stress were examined in hearts of 25-week old mice. Total ROS as determined
9 by DCFDA assay in whole cardiac homogenates and malondialdehyde (MDA) were
10 similar between Con and G4H$^{-/-}$ mice (Figure 1A, B). In isolated mitochondria, hydrogen
11 peroxide concentrations and aconitase activity were unchanged as well (Figure 1C, D).
12 Cytosolic aconitase activity was not altered in G4H$^{-/-}$ compared to Con mice (Figure 1E).
13 While concentrations of GSH (reduced glutathione) in whole cardiac homogenates was
14 unchanged in G4H$^{-/-}$ mice, the amount of GSSG (oxidized glutathione) was significantly
15 greater such that GSH:GSSG was lower in G4H$^{-/-}$ mice compared to Con (Figure 1F-H).
16 In 5-week-old mice prior to the onset of cardiac hypertrophy, a similar pattern of
17 increased GSSG leading to reduced GSH:GSSG ratios were observed (Table 1).
18 Interestingly, at 8-weeks of age, the reduction in GSH:GSSG ratios were secondary to
19 reduced GSH that was associated with a more modest increase in GSSG (Table 2). In
20 isolated mitochondria an increase in GSSG and reduced GSH:GSSG ratios were
21 observed in G4H$^{-/-}$ hearts (Table 3).

22

23 **Tempol Treatment**

24 Since increased cardiac oxidized glutathione concentrations preceded cardiac
25 hypertrophy, we hypothesized that oxidative stress contributed to the hypertrophic

University of Utah Institutional Repository
Author Manuscript

1 phenotype in G4H$^{-/-}$ mice. To test this, the antioxidant tempol was administered as a 1
2 mM solution in drinking water. Overall water consumption was unchanged among
3 treated vs. untreated mice (data not shown). Body weight and tibia length were also
4 unchanged during the 4-week treatment period (Table 2). Tempol prevented cardiac
5 hypertrophy in G4H$^{-/-}$ mice as evidenced by similar heart weight and heart:tibia length in
6 tempol treated G4H$^{-/-}$ mice vs. control mice (Table 2). GSH:GSSG was lower in all G4H$^{-/-}$
7 compared to all Con, and tempol treatment did not alter this ratio (Table 2).
8 To assess if the changes in the GSH:GSSG ratio in G4H$^{-/-}$ hearts could be
9 accounted for by upregulation of glutathione peroxidase (GPX) and/or downregulation of
10 glutathione reductase (GR) we measured RNA and protein levels of these enzymes.
11 There was no difference in either GR gene transcripts or protein in hearts of Con vs.
12 G4H$^{-/-}$ mice (Figures 2a, 3a). There was also no change in gene expression of GPX4
13 and GPX1 in hearts of G4H$^{-/-}$ mice vs. Con (Figure 2a). Protein expression of GPX4 in
14 untreated G4H$^{-/-}$ mice was inconsistent between cohorts used for the tempol and
15 MnTBAP studies. For example, in the tempol study GPX4 was greater in G4H$^{-/-}$ mice vs.
16 Con, but in the MnTBAP cohort, where both G4H$^{-/-}$ and Con received daily intraperitoneal
17 injections of saline, GPX4 was similar (Figure 3). Although there were minor changes in
18 GPX4 expression levels in tempol-treated G4H$^{-/-}$, protein levels were not modulated by
19 tempol in control or G4H$^{-/-}$ mouse hearts, respectively. Similarly, small changes in
20 glutathione reductase protein, in the MnTBAP cohort are unlikely to account for the
21 differences observed in GSH:GSSG ratios.
22 NOX2 is a generator of cytosolic superoxide that is located on the cell
23 membrane. Full activation of NOX2 requires assembly with p67^{phox} (also known as
24 NOXA1) and p47^{phox} subunits before superoxide can be produced. Expression of the
25 p67^{phox} gene was similar among all mice (Figure 2a). Expression of p47^{phox} remained

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 similar among all groups (Figure 2a). The protein levels of $p67^{phox}$ subunit of NOX2 in
2 cardiac membrane fractions were markedly greater in $G4H^{-/-}$ vs. Con, suggesting an
3 increase in NOX2 activation. Protein levels of $p67^{phox}$ in the cytosol were unchanged
4 (data not shown). The activation state of NOX2 remained unchanged in $G4H^{-/-}$+T mice
5 as the membrane localization of $p67^{phox}$ protein was similar to untreated $G4H^{-/-}$ (Figure
6 4). Thioredoxin (TXN2) expression, a redox-active molecule that is found in cardiac
7 mitochondria, was increased in $G4H^{-/-}$ mice vs. Con, but, similar between Con+T and
8 $G4H^{-/-}$+T (Figure 2a).

9 The reduction in cardiac hypertrophy resulting from tempol treatment in $G4H^{-/-}$
10 mice was accompanied by the reduction of some, but not all of the classic genetic
11 markers of hypertrophy. In $G4H^{-/-}$ mice α-MHC, brain naturetic peptide (BNP), SERCA2a,
12 and SERCA2b were unchanged compared to Con, and were not further affected by
13 tempol treatment (Figure 2b). In contrast to the present study, our original study
14 characterizing $G4H^{-/-}$ mice found increases in BNP[14]. We believe that the most likely
15 basis for this difference is that our previous work used only male mice aged 13-14
16 weeks, and northern blots were employed to detect BNP expression, whereas the
17 current study used a mixed cohort of 8-week old males and females, and real time PCR
18 was used to detect transcripts. Expression of atrial naturetic factor (ANF), on the other
19 hand, was increased in $G4H^{-/-}$ mice vs. Con. While there was a trend present (p=0.06)
20 toward increased β-myosin heavy chain (MHC) between Con and $G4H^{-/-}$ mice, this was
21 not statistically significant (Figure 2b). β-MHC expression was similar in tempol treated
22 Con and $G4H^{-/-}$ mice (Figure 2b). Consistent with previous reports [14], GLUT1
23 expression was higher in $G4H^{-/-}$ compared to Con (Figure 2b).

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 Glycogen synthase kinase (GSK) 3β inactivation has been reported to play a role
2 in other diabetic models of cardiac hypertrophy [19]. To determine if tempol reduced
3 cardiac hypertrophy in G4H$^{-/-}$ mice through an oxidative stress independent mechanism,
4 we measured phosphorylated -(p) GSK3β and total GSK3β in hearts of Con and G4H$^{-/-}$
5 mice. Our data indicated that the ratio of p-GSK3β to total GSK3β was unchanged
6 between Con and G4H$^{-/-}$ mice, and that tempol did not affect GSK3β activation in either
7 group (Figure 5).
8

9 **MnTBAP treatment.**

10 Isolated mitochondria of G4H$^{-/-}$ mice had greater GSSG and reduced GSH:GSSG
11 compared to control mice (Table 3). To determine if a mitochondrial oxidative stress was
12 a contributor to cardiac hypertrophy in G4H$^{-/-}$ mice, we used the mitochondrial targeted
13 antioxidant MnTBAP. A 4-week treatment with MnTBAP increased mitochondrial GSH in
14 G4H-/- mice compared to saline treated G4H$^{-/-}$. MnTBAP also lowered GSSG and
15 increased GSH:GSSG in G4H$^{-/-}$ mice to levels similar to controls. However, this
16 improvement in mitochondrial oxidative stress was not accompanied by a reduction in
17 heart weight or cardiac hypertrophy (Table 3). These data indicate that while
18 mitochondrial oxidative stress is present in G4H$^{-/-}$ mice, it is unlikely to be the basis for
19 the development of cardiac hypertrophy. MntBAP treatment did not produce any change
20 in mRNAs for GR, GPX1 or TXN2. There was also no effect of MnTBAP treatment on
21 GPX4 protein and the small reduction in GR cannot account for changes in GSH:GSSG
22 that was observed.
23

24 **DISCUSSION**

University of Utah Institutional Repository
Author Manuscript

The major findings of this study are that G4H$^{-/-}$ mice have signs of low level oxidative stress in the heart since both whole cell homogenate and mitochondrial preparations had lower GSH:GSSG. The reduction in GSH:GSSG was seen in mice as young as 5 weeks old, prior to the presence of significant cardiac hypertrophy, suggesting a role for oxidative stress in the pathogenesis of hypertrophy. G4H$^{-/-}$ mice also had increased protein expression of p67^{phox}. Treatment with a general membrane permeable antioxidant, tempol, prevented cardiac hypertrophy, while the mitochondrial-targeted antioxidant, MnTBAP, did not affect development of hypertrophy. Tempol treatment did not reverse the membrane localization of p67^{phox} and did not normalize GSH:GSSG, so the possibility remains that the impact of tempol on cardiac hypertrophy could be an off target effect that is unrelated to oxidative stress. However, the MnTBAP experiments presented in this study strongly suggest that mitochondrial oxidative stress is unlikely to play a role in cardiac hypertrophy in G4H$^{-/-}$ hearts.

Our conclusion that G4H$^{-/-}$ mice have low-level oxidative stress is based on data indicating that there was no difference between many indicators of oxidative stress in Con vs. G4H$^{-/-}$ mice, whereas glutathione concentrations were consistently altered in G4H$^{-/-}$ mice. In agreement with our study, previous studies using rodents have also reported changes in glutathione ratio without alterations in other markers of oxidative stress, such as lipid peroxidation [20]. This suggests that the status of glutathione is a sensitive indicator of the redox state of the heart. Glutathione is a major antioxidant in the cell and it is well known that oxidative stress consumes reduced glutathione (GSH). Increases in oxidized cardiac glutathione are widely reported in rodents with hypertrophy, heart failure, and/or diabetes [21-24]. Changes in the ratio of oxidized versus reduced glutathione, could be secondary to differences in the expression or activity of enzymes that mediate the interconversion of GSH and GSSH, or to differences

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 in the concentration of proton donors or acceptors. GPX4 protein levels were actually
2 lower and GR protein levels were unchanged between Con and G4H$^{-/-}$ mice. Thus
3 enzyme levels cannot account for the differences observed, although changes in activity
4 cannot be ruled out.

5 This current study follows a previous report by Ritchie et al. that used a different
6 model wherein cardiac specific GLUT4 deletion was superimposed upon reduced
7 GLUT4 expression in all tissues [15]. There were several points of similarity between our
8 study and the aforementioned one. Ritchie et al. reported that tempol reduced both
9 cardiac hypertrophy without any change in NOX2 mediated superoxide production [15].
10 Similarly, we also found that tempol attenuated hypertrophy and that translocation of
11 p67^{phox} in G4H$^{-/-}$ mice was not affected. However, there are also several important
12 differences between the experimental design and methods of the current study and the
13 one by Ritchie et al. For example, 1) the G4H$^{-/-}$ mouse used in our study is a specific
14 model of cardiac specific GLUT4 deletion, whereas the model used by Ritchie et al. has
15 very low, but not completely deleted levels cardiac GLUT4 protein that is superimposed
16 on whole body GLUT4 knockdown, 2) our model does not have insulin resistance,
17 whereas the model used by Ritchie et al. does, 3) we examined a number of markers of
18 oxidative stress in both cytosol and mitochondria, 4) we conducted additional
19 experiments with another antioxidant (MnTBAP) to evaluate the potential contribution of
20 mitochondrial-specific oxidative stress to the development of cardiac hypertrophy. The
21 effectiveness of MnTBAP to reduce mitochondrial superoxide has been previously
22 demonstrated *in vitro* and *in vivo* using oxygen-glucose depleted cortical cell cultures
23 [25] and SOD2 null mice [26]. Furthermore, since mitochondria have a negative resting
24 potential, it is thought that they can accumulate positively charged antioxidant
25 compounds such as MnTBAP (containing Mn^{3+}).

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript
UU IR Author Manuscript

1 One of the aims of this study was to determine if the source of oxidative stress
2 was mitochondrial or cytosolic in origin. General parameters of oxidative stress such as
3 malondialdehyde levels, cytosolic aconitase, and whole cell superoxide production were
4 unchanged. In isolated mitochondria, aconitase activity and hydrogen peroxide
5 concentrations were also unchanged. In spite of this both whole cell and mitochondrial
6 GSH:GSSG was lower. Taken together these data suggest that while overt oxidative
7 stress does not exist, there is a degree of mild oxidative stress present in both
8 mitochondria and whole homogenates. Use of two unique antioxidants (tempol and
9 MnTBAP) allowed us to determine which ROS generating compartment was critical to
10 the phenotype of cardiac hypertrophy. The fact that MnTBAP treatment lowered oxidized
11 glutathione concentrations and improved GSH:GSSG in mitochondria without a
12 concomitant reduction of cardiac hypertrophy, supports the conclusion that mitochondrial
13 oxidative stress is not an important driver of the hypertrophy in G4H$^{-/-}$ mice. Tempol
14 treatment, on the other hand, markedly attenuated hypertrophy. G4H$^{-/-}$ mice also
15 displayed persistent translocation of p67^{phox} (Figure 4) indicating activation of NOX2 and
16 superoxide production. Given the importance of NOX2 as a major source of cytosolic
17 oxidative stress and its role in cardiac hypertrophy [27-29], it is likely that NOX2 could be
18 a cytosolic driver of cardiac hypertrophy in the G4H$^{-/-}$ mouse. However, tempol treatment
19 did not alter the translocation of p67^{phox}, nor were any changes in NOX activity observed
20 by Ritchie et al[15, 30]. Taken together, these studies suggest that cytosolic sources of
21 oxidative stress, rather than mitochondrial, are contributing to the hypertrophic
22 phenotype, although neither our study nor that of Ritchie et al. have specifically
23 elucidated the precise source of cytosolic ROS that mediates this effect.
24 In spite of the reduction in hypertrophy after tempol treatment, whole cell
25 GSH:GSSG was not improved in G4H$^{-/-}$+T mice. There are 2 possible explanations for

University of Utah Institutional Repository
Author Manuscript

1 the lack of change in glutathione concentrations. 1) Either tempol exerts it action due to
2 an off target or nonspecific effect that is unrelated to oxidative stress, or 2) glutathione
3 concentrations in whole homogenates may not specifically reflect cytosolic glutathione
4 concentrations. With regard to the latter point, whole cardiac tissue was homogenized to
5 obtain GSH and GSSG concentrations. Mitochondria extracts present in this whole
6 homogenate contributed to the levels of GSSG measured. It is possible that if the
7 dosage of tempol used in this study did not successfully reduce mitochondrial GSSG
8 levels, then the whole cell assay may reflect a GSH:GSSG concentration that is
9 unchanged due to the contribution from the mitochondria. In support of this, it has been
10 reported that tempol does not have a strong affinity for accumulating in mitochondria,
11 and is only weakly reduced by the mitochondrial CoQ pool [31]. In contrast, mitoTempol,
12 a mitochondrial targeted version of tempol, accumulates 100 fold greater in mitochondria
13 and is strongly reduced by the mitochondrial CoQ pool [31]. Interestingly, there are other
14 reports of i.v. tempol infusion failing to alter GSH:GSSG in skeletal muscle homogenates
15 [32], and that at least 4 weeks of tempol treatment (1mM in drinking water) were required
16 prior to improvement of GSH:GSSG in the heart. Thus a limitation of this study is the fact
17 that we did not measure cytosolic levels of GSH and GSSG.

18 Since it was possible that tempol attenuated hypertrophy in G4H$^{-/-}$ mice through off
19 target mechanisms that may be unrelated to oxidative stress, we examined two
20 alternative mechanisms; GLUT1 expression and GSK3β activation. GLUT1 is a related
21 and constitutively active glucose transporter. A compensatory increase in GLUT1
22 expression could re-establish normal glucose supply and rescue the heart from GLUT4
23 deficiency. Though we confirmed our previous findings that G4H$^{-/-}$ mice have an increase
24 in GLUT1 expression [14], we did not find that tempol treatment increased GLUT1
25 expression further, but instead decreased it. Alternatively, GSK activation has been

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 reported to play a role in cardiac hypertrophy in other models of diabetes. For example,
2 in diabetes produced by streptozotocin treatment, GSK3β is less phosphorylated (more
3 active) in the hypertrophied heart of rodent models of diabetes [19]. Furthermore, when
4 these rats are treated with tempol, the phosphorylation of GSK3β is increased, it
5 becomes less active, and hypertrophy is subsequently reduced [19]. However, we did
6 not observe any change in GSK3β activation in G4H$^{-/-}$ vs. Con mice, either before or
7 after tempol treatment. In line with our data, Richie et al. found no change in GSK3β
8 gene expression in hearts of mice with GLUT4 deletion superimposed on whole body
9 GLUT4 suppression[15]. However, they also reported a significant increase in GSK3β
10 expression following tempol treatment, whereas we saw no change. It is important to
11 note that we assessed GSK3β status by measuring both total and phosphorylated
12 GSK3β protein rather than changes in mRNA. While we can speculate that GSK3β
13 activation may be altered earlier in the development phase of hypertrophy (i.e. between
14 4 and 7 weeks of age), our present data does not support a role for GSK3β in the G4H$^{-/-}$
15 mice. Another possible mechanism that could have mediated the observed reduction in
16 cardiac hypertrophy in G4H$^{-/-}$ mice is reduction of blood pressure. A limitation of this
17 study is that we did not measure blood pressure, however, it should be noted that there
18 was no genetic manipulation of blood pressure regulating tissues such as arteries,
19 kidneys, and brain, and that these mice had normal whole body metabolic profile, in spite
20 of GLUT4 deletion in the heart. Therefore, we speculate that blood pressure was unlikely
21 to be a factor.

22 The G4H$^{-/-}$ mouse was originally developed to study the importance of insulin
23 mediated glucose uptake in cardiac function [14]. As such the development of cardiac
24 hypertrophy due to GLUT4 deletion in this model was an unexpected finding. Data from

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

our present study indicates that oxidative stress may contribute to the development of cardiac hypertrophy. While this notion has been confirmed by a previous study that used tempol to reduce hypertrophy in a different model of cardiac specific GLUT4 deletion that was superimposed on whole body GLUT4 suppression, the cellular source of ROS that drove hypertrophy remained elusive. In the present study, both the increased membrane translocation of $p67^{phox}$ and the efficacy of tempol to prevent hypertrophy suggest that the source of ROS in $G4H^{-/-}$ mice appears to be cytosolic. Furthermore, we demonstrate that improving mitochondrial redox state through the use of MnTBAP does not reduce hypertrophy. Therefore, the contribution of mitochondrial ROS to cardiac hypertrophy in cardiac specific GLUT4 deletion may be ruled out.

MATERIALS AND METHODS

Animals and methods for initial evaluation of markers of oxidative stress.

All protocols were approved by the University of Utah Institutional Animal Care and Use Committee. Mice with cardiac specific deletion of GLUT4 were generated as previously described ($G4H^{-/-}$) [14]. Littermates with normal GLUT4 expression were used as controls (Con). Mixed cohorts of male and female mice were used for all studies since both develop cardiac hypertrophy as previously described [14]. All animals were kept on a 12 h light : dark cycle, and all experiments were conducted on random fed mice. Adult Con and $G4H^{-/-}$ mice (25±3 weeks old) were first used to determine status of markers of oxidative stress prior to conducting antioxidant treatment experiments.

Aconitase activity

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

Cardiac aconitase activity was measured in cytosolic fractions and isolated mitochondria as previously described using succinate as a metabolic substrate [33, 34]. Aconitase activity has been previously shown to be sensitive to oxidative stress[34]. Assays were conducted in 50 mM Tris-HCl (pH 7.5) buffer containing 20 mM cis-aconitic acid. The rate of change of absorbance was followed for 10 min at 240 nm, with the activity expressed as mmol cis-aconitate used/min/mg of protein.

Hydrogen peroxide concentrations.

Mitochondrial H_2O_2 generation was measured as previously described [35, 36]. This method uses a spectro-fluorophotometer (RF5301PC; Shimadzu, Columbia, MD) that monitors H_2O_2-induced fluorescence of homovanillic acid (excitation wavelength 312 nm, emission wavelength 420) in the prescence of horseradish peroxidase as a catalyst. Succinate (4 mmol/l) was used to stimulate ROS production after inhibition of the F_1F_0-ATP synthase with oligomycin (1 μmol). Rotenone (10 μmol /L) was then added to the mixture to stop complex I–mediated superoxide production. Data is expressed as μmol / L / min / mg mitochondrial protein.

Determination of reactive oxygen species.

The presence of reactive oxygen species in cardiac homogenates were evaluated by using a method to measure the conversion of non-fluorescent dichlorodihydrofluorescein diacetate (DCFDA) to 2’, 7’ – dichlorofluorescein (DCF) upon oxidation with free radicals [37]. Briefly, cardiac homogenates were prepared by homogenizing 50 mg of tissue in buffer containing 50 mM phospohate buffer, 1mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 1 μM pepstatin, 80 mg/L trypsin inhibitor at

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 pH 7.4 and centrifuging as previously described [36]. Both DCFDA and H2DCFDA were
2 added to cardiac homogenates to achieve a 25μM final concentration. Excitation at 485
3 nm and emission at 530 nm were then measured at 0 and 30 min at 37°C. Data is
4 expressed as nmol DCF/mg protein/min.
5
6 **Measurement of cardiac malondialdehyde (MDA) concentrations.**
7 MDA concentrations were measured using LPO-586™ assay (Oxis Research,
8 Portland, OR). Heart tissue was weighed and homogenized in 6 volumes of ice-cold
9 phosphate-buffered saline (PBS, 20 mM, pH 7.4) containing 10 ml 0.5 M BHT in
10 acetonitrile (to prevent sample oxidation during homogenization). After brief sonication,
11 the homogenate was centrifuged at 3000 g at 4°C for 10 min and supernatant used to
12 determine the concentration of MDA by incubating with 650 μl of diluted chromogenic
13 reagent, N-methyl-2-phenylindole, at 45°C for 60 min. After incubation with the
14 chromogenic agent, samples were centrifuged at 15,000 g for 10 min to obtain a clear
15 supernatant in which absorbance at 586 nm was measured. Results are reported as
16 nmol / g heart tissue used.
17
18 **Determination of glutathione concentrations in whole homogenates.**
19 Concentrations of oxidized (GSSG) and reduced (GSH) glutathione were
20 determined using a kit from Oxis International (Foster City, CA), following the
21 manufacturer's instructions. Both total GSSG and the ratio of GSH:GSSG was used as
22 an index of oxidative stress. To determine whole heart GSH concentrations,
23 approximately 25-35 mg of ventricular tissue was homogenized in 10 volumes of 5% ice
24 cold metaphosphoric acid (MPA). For measurement of GSSG, a similar sized heart
25 sample was homogenized with MPA and supplemented with 30μL M2VP to block the

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 further oxidation of GSH to GSSG. All samples were done in duplicate and
2 concentrations (nmol) of glutathione were normalized to ventricular tissue sample (g)
3 used.
4
5 **Antioxidant treatments.**
6 Four-week old mice were given free access to water (Con; n=6, G4H$^{-/-}$; n=7) or
7 water with 1 mM tempol as previously described [15] (Con +T; n=7, G4H$^{-/-}$+T n=7) for 4
8 weeks. Previous studies have used a similar dosage of tempol in other models to
9 successfully reduce oxidative stress [17, 38]. Water consumption was monitored daily
10 during the treatment period to verify that the presence of tempol did not affect water
11 intake. In a second experiment using an alternative antioxidant, 4-week old G4H$^{-/-}$ mice
12 were treated every other day for 4 weeks with 10 mg/kg Mn(III) tetrakis (4-benzoic acid)
13 porphyrin chloride (MnTBAP, i.p.) or saline-vehicle (Con + Veh; n=22, G4H$^{-/-}$+ Veh;
14 n=19, Con + MnTBAP; n=26, G4H$^{-/-}$+ MnTBAP; n=23). At the end of both tempol and
15 MnTBAP treatments, mice were anesthetized using chloral hydrate (90 mg/kg) and the
16 heart was removed, rinsed and weighed. Hearts were then used to determine indices of
17 oxidative stress from whole homogenates after tempol treatment or isolated
18 mitochondria after MnTBAP treatments.
19
20 **Determination of mitochondrial glutathione concentrations after MnTBAP**
21 **treatment.**
22 Freshly prepared mitochondria from individual hearts were isolated using STE1
23 buffer (pH 7.4) [250mM sucrose, 5mM tris-HCl, and 2mM EGTA (Sigma-Aldrich, Inc., St.
24 Louis, MO)] and STE2 buffer (pH 7.4) [STE1 plus, 0.5% bovine serum albumin, 5mM

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

$MgCl_2$, 1mM ATP, and 2.5U/ml Sigma protease (Sigma-Aldrich, Inc., St. Louis, MO)] as previously described [39]. Ventricles were chopped in 4 ml ice-cold STE1 buffer 2 ~ 3 times to wash out blood. After a 4-min digestion period in ice cold STE2, the digested tissue was washed in 5ml STE1 buffer and then homogenized on ice. Homogenates were centrifuged at 8,000g (4°C) for 10 minutes, re-suspended in 4 ml ice-cold STE1 buffer, and centrifuged at 700g (4°C) for 10 minutes to separate mitochondria from other organelles. Finally, the supernatant (containing mitochondria) was centrifuged at 8,000g (4°C) for 10 minutes to wash out low-molecular weight impurities.

To determine glutathione concentrations, fresh mitochondria were suspended in 2.4 ml of ice-cold STE1 buffer, and aliquoted into 2 portions. Both aliquots were then centrifuged at 8000g (4°C), and the pellets recovered. For GSSG measurement, one aliquot was suspended in 0.45 volumes of ice-cold thiol- scavenger M2VP (Oxis International Inc., Portland, OR) plus 1.05 volumes of ice-cold 5% MPA (Sigma-Aldrich, Inc., St. Louis, MO). The other aliquot, used for determination of GSH, was suspended in 2 volumes of ice-cold 5% MPA. Pellets were then snap frozen in liquid nitrogen and then stored under -140°C for later analysis using a kit from Oxis International (Foster City, CA), following the manufacturer's instructions. Mitochondrial GSH and GSSG concentrations (nmol) were normalized to mitochondrial protein (mg) content.

Western blotting for p67^{phox} protein expression after tempol treatment.

Homogenization of hearts and western blotting was done as previously described [40, 41]. Antibodies directed against p67^{phox}, a subunit of NADPH oxidase, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Signals were visualized by enhanced chemiluminescence (Cell Signal Technology, Beverly, MA). After exposure, membranes were stripped and probed with glyceraldehyde-3-phosphate dehydrogenase

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 (GAPDH) as a loading control (Chemicon, Temecula, CA). Blots were prepared in
2 triplicate and relative band densities were measured using a Kodak GL1500 gel imaging
3 system.
4
5 **Real time PCR (RT-PCR)**
6 RNA extraction and quantitative RT-PCR was performed as previously described
7 [42]. Total RNA was extracted from hearts with TRizol reagent (Invitrogen Corporation,
8 Carlsbad, CA) and 3 μg of RNA were reverse transcribed using Superscript III Reverse
9 Transcriptase (Invitrogen). Primers used for Brian Natiuretic Peptide (BNP),
10 sarcoplasmic reticulum calcium ATPase (SERCA) 2a & 2b, α-myosin heavy chain (α-
11 MHC), β-myosin heavy chain (β-MHC), atrial natriuretic factor (ANF), glucose transporter
12 1 (GLUT1), glutathione reductase (GR), glutathione peroxidase-1 (GPX1), glutathione
13 peroxidase-4 (GPX4), thioredoxin-2 (TXN2), $p47^{phox}$, and $p67^{phox}$ are shown in Table 4.
14 The resulting cDNA were subjected to quantitative real-time RT-PCR. All reactions were
15 performed in triplicate. Relative quantification was performed by interpolating crossing
16 point data on an independent standard curve. Product size was confirmed by melting
17 curve and agarose gel electrophoresis with ethidium bromide staining. Data were
18 corrected for loading relative to the levels of the invariant transcript cyclophilin (Table 4)
19 and normalized to $GLUT4^{+/+}$ controls (a.u. = 1.0).
20
21 **Statistics**
22 A t-test was used to detect significant differences in between control and $G4H^{-/-}$
23 mice during initial studies. A 2 way ANOVA (SPSS v.20) was used to determine
24 significant differences among groups when treated with MnTBAP or Tempol. A

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

Bonferroni post-hoc test was used when main effects were detected after ANOVA. Significance was accepted at $P<0.05$. All data is expressed as mean±SEM.

Acknowledgements

This study was supported by NIH HL085226 to TJ, and UO1 HL 70525 & 087947 to EDA, who is an established investigator of the AHA.

UU IR Author Manuscript

UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 **References**

2 1. Bertoni AG, Tsai A, Kasper EK & Brancati FL (2003) Diabetes and idiopathic
3 cardiomyopathy: a nationwide case-control study. *Diabetes Care* **26**, 2791-2795.
4 2. Francis GS (2001) Diabetic cardiomyopathy: fact or fiction? *Heart* **85**, 247-248.
5 3. Hirayama H, Sugano M, Abe N, Yonemochi H & Makino N (2000) Determination
6 of left ventricular mass by echocardiography in normotensive diabetic patients. *Jpn Circ*
7 *J* **64**, 921-924.
8 4. Levy D, Garrison RJ, Savage DD, Kannel WB & Castelli WP (1990) Prognostic
9 implications of echocardiographically determined left ventricular mass in the
10 Framingham Heart Study. *N Engl J Med* **322**, 1561-1566.
11 5. Cai L & Kang YJ (2001) Oxidative stress and diabetic cardiomyopathy: a brief
12 review. *Cardiovasc Toxicol* **1**, 181-193, doi: CT:1:3:181 [pii].
13 6. Fiordaliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, De Angelis N,
14 Ghezzi P, Latini R & Masson S (2006) Cardiovascular oxidative stress is reduced by an
15 ACE inhibitor in a rat model of streptozotocin-induced diabetes. *Life Sci* **79**, 121-129, doi:
16 S0024-3205(05)01272-5 [pii]
17 10.1016/j.lfs.2005.12.036.
18 7. Kakkar R, Mantha SV, Kalra J & Prasad K (1996) Time course study of oxidative
19 stress in aorta and heart of diabetic rat. *Clin Sci (Lond)* **91**, 441-448.
20 8. Ritchie RH & Delbridge LM (2006) Cardiac hypertrophy, substrate utilization and
21 metabolic remodelling: cause or effect? *Clin Exp Pharmacol Physiol* **33**, 159-166.
22 9. An D, Kewalramani G, Chan JK, Qi D, Ghosh S, Pulinilkunnil T, Abrahani A, Innis
23 SM & Rodrigues B (2006) Metformin influences cardiomyocyte cell death by pathways
24 that are dependent and independent of caspase-3. *Diabetologia* **49**, 2174-2184, doi:
25 10.1007/s00125-006-0338-9.

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

10. Seddon M, Looi YH & Shah AM (2007) Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. *Heart* **93**, 903-907, doi: hrt.2005.068270 [pii] 10.1136/hrt.2005.068270.

11. Takimoto E & Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. *Hypertension* **49**, 241-248, doi: 01.HYP.0000254415.31362.a7 [pii] 10.1161/01.HYP.0000254415.31362.a7.

12. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF & Sadoshima J (2003) Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. *J Clin Invest* **112**, 1395-1406, doi: 10.1172/JCI17700
112/9/1395 [pii].

13. Lu Z, Xu X, Hu X, Zhu G, Zhang P, van Deel ED, French JP, Fassett JT, Oury TD, Bache RJ, et al. (2008) Extracellular superoxide dismutase deficiency exacerbates pressure overload-induced left ventricular hypertrophy and dysfunction. *Hypertension* **51**, 19-25, doi: HYPERTENSIONAHA.107.098186 [pii]
10.1161/HYPERTENSIONAHA.107.098186.

14. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, et al. (1999) Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. *J Clin Invest* **104**, 1703-1714.

15. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, Proietto J & Delbridge LM (2007) The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. *J Mol Cell Cardiol* **42**, 1119-1128, doi: S0022-2828(07)00882-6 [pii]
10.1016/j.yjmcc.2007.03.900.

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 16. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M,
2 Suzuki T, Maeta H & Abe Y (2005) Role of NAD(P)H oxidase- and mitochondria-derived
3 reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin
4 II. *Hypertension* **45**, 860-866, doi: 01.HYP.0000163462.98381.7f [pii]
5 10.1161/01.HYP.0000163462.98381.7f.
6 17. Mariappan N, Soorappan RN, Haque M, Sriramula S & Francis J (2007) TNF-
7 alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by
8 superoxide dismutase mimetic Tempol. *Am J Physiol Heart Circ Physiol* **293**, H2726-
9 2737, doi: 00376.2007 [pii]
10 10.1152/ajpheart.00376.2007.
11 18. Tian R & Abel ED (2001) Responses of GLUT4-deficient hearts to ischemia
12 underscore the importance of glycolysis. *Circulation* **103**, 2961-2966.
13 19. Gurusamy N, Watanabe K, Ma M, Prakash P, Hirabayashi K, Zhang S, Muslin
14 AJ, Kodama M & Aizawa Y (2006) Glycogen synthase kinase 3beta together with 14-3-3
15 protein regulates diabetic cardiomyopathy: effect of losartan and tempol. *FEBS Lett* **580**,
16 1932-1940, doi: 10.1016/j.febslet.2006.02.056.
17 20. Sanders RA, Rauscher FM & Watkins JB, 3rd (2001) Effects of quercetin on
18 antioxidant defense in streptozotocin-induced diabetic rats. *J Biochem Mol Toxicol* **15**,
19 143-149, doi: 10.1002/jbt.11 [pii].
20 21. Dhalla AK & Singal PK (1994) Antioxidant changes in hypertrophied and failing
21 guinea pig hearts. *Am J Physiol* **266**, H1280-1285.
22 22. Hayashi K, Kimata H, Obata K, Matsushita A, Fukata A, Hashimoto K, Noda A,
23 Iwase M, Koike Y, Yokota M, et al. (2008) Xanthine oxidase inhibition improves left
24 ventricular dysfunction in dilated cardiomyopathic hamsters. *J Card Fail* **14**, 238-244,
25 doi: S1071-9164(07)01129-3 [pii]

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 10.1016/j.cardfail.2007.11.001.

2 23. de Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG & Ferder L (2001)
3 Enalapril attenuates oxidative stress in diabetic rats. *Hypertension* **38**, 1130-1136.

4 24. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H,
5 Murohara T & Yokota M (2006) Mineralocorticoid receptor antagonism attenuates
6 cardiac hypertrophy and failure in low-aldosterone hypertensive rats. *Hypertension* **47**,
7 656-664, doi: 01.HYP.0000203772.78696.67 [pii]
8 10.1161/01.HYP.0000203772.78696.67.

9 25. Li QY, Pedersen C, Day BJ & Patel M (2001) Dependence of excitotoxic
10 neurodegeneration on mitochondrial aconitase inactivation. *J Neurochem* **78**, 746-755.

11 26. Melov S, Schneider JA, Day BJ, Hinerfeld D, Coskun P, Mirra SS, Crapo JD &
12 Wallace DC (1998) A novel neurological phenotype in mice lacking mitochondrial
13 manganese superoxide dismutase. *Nat Genet* **18**, 159-163, doi: 10.1038/ng0298-159.

14 27. Bendall JK, Cave AC, Heymes C, Gall N & Shah AM (2002) Pivotal role of a
15 gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in
16 mice. *Circulation* **105**, 293-296.

17 28. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC & Shah
18 AM (2003) Contrasting roles of NADPH oxidase isoforms in pressure-overload versus
19 angiotensin II-induced cardiac hypertrophy. *Circ Res* **93**, 802-805, doi:
20 10.1161/01.RES.0000099504.30207.F5.

21 29. Li JM, Gall NP, Grieve DJ, Chen M & Shah AM (2002) Activation of NADPH
22 oxidase during progression of cardiac hypertrophy to failure. *Hypertension* **40**, 477-484.

23 30. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, Proietto
24 J & Delbridge LM (2007) The antioxidant tempol inhibits cardiac hypertrophy in the

UU IR Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 insulin-resistant GLUT4-deficient mouse in vivo. *Journal of molecular and cellular*
2 *cardiology* **42**, 1119-1128, doi: 10.1016/j.yjmcc.2007.03.900.
3 31. Trnka J, Blaikie FH, Smith RA & Murphy MP (2008) A mitochondria-targeted
4 nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. *Free radical*
5 *biology & medicine* **44**, 1406-1419, doi: 10.1016/j.freeradbiomed.2007.12.036.
6 32. Kim BS, Cha HN, Kim YW, Kim JY, Dan JM & Park SY (2009) Inhibition of lipid
7 infusion-induced skeletal muscle insulin resistance by cotreatment with tempol and
8 glutathione in mice. *J Pharmacol Sci* **110**, 370-380.
9 33. Jouihan HA, Cobine PA, Cooksey RC, Hoagland EA, Boudina S, Abel ED, Winge
10 DR & McClain DA (2008) Iron-mediated inhibition of mitochondrial manganese uptake
11 mediates mitochondrial dysfunction in a mouse model of hemochromatosis. *Mol Med* **14**,
12 98-108, doi: 10.2119/2007-00114.Jouihan.
13 34. Yan LJ, Levine RL & Sohal RS (1997) Oxidative damage during aging targets
14 mitochondrial aconitase. *Proc Natl Acad Sci U S A* **94**, 11168-11172.
15 35. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI,
16 Bugger H, Zaha VG, et al. (2007) Mitochondrial energetics in the heart in obesity-related
17 diabetes: direct evidence for increased uncoupled respiration and activation of
18 uncoupling proteins. *Diabetes* **56**, 2457-2466, doi: 10.2337/db07-0481.
19 36. Barja G (1999) Mitochondrial oxygen radical generation and leak: sites of
20 production in states 4 and 3, organ specificity, and relation to aging and longevity. *J*
21 *Bioenerg Biomembr* **31**, 347-366.
22 37. Kim HJ, Kim KW, Yu BP & Chung HY (2000) The effect of age on
23 cyclooxygenase-2 gene expression: NF-kappaB activation and IkappaBalpha
24 degradation. *Free Radic Biol Med* **28**, 683-692, doi: S0891-5849(99)00274-9 [pii].

UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 38. Banday AA, Marwaha A, Tallam LS & Lokhandwala MF (2005) Tempol reduces
2 oxidative stress, improves insulin sensitivity, decreases renal dopamine D1 receptor
3 hyperphosphorylation, and restores D1 receptor-G-protein coupling and function in
4 obese Zucker rats. *Diabetes* **54**, 2219-2226, doi: 54/7/2219 [pii].
5 39. Brand MD, Pakay JL, Ocloo A, Kokoszka J, Wallace DC, Brookes PS & Cornwall
6 EJ (2005) The basal proton conductance of mitochondria depends on adenine
7 nucleotide translocase content. *Biochem J* **392**, 353-362, doi: BJ20050890 [pii]
8 10.1042/BJ20050890.
9 40. Avelar E, Jalili T, Dong L, Arvizo J, Hu P, Litwin SE & Mattson JP (2005) PKC
10 translocation and ERK1/2 activation in compensated right ventricular hypertrophy
11 secondary to chronic emphysema. *BMC Physiol* **5**, 6.
12 41. Jalili T, Takeishi Y, Song G, Ball NA, Howles G & Walsh RA (1999) PKC
13 translocation without changes in Galphaq and PLC-beta protein abundance in cardiac
14 hypertrophy and failure. *Am J Physiol* **277**, H2298-2304.
15 42. Symons JD, Hu P, Yang Y, Wang X, Zhang QJ, Wende AR, Sloan CL, Sena S,
16 Abel ED & Litwin SE (2011) Knockout of insulin receptors in cardiomyocytes attenuates
17 coronary arterial dysfunction induced by pressure overload. *American journal of*
18 *physiology Heart and circulatory physiology* **300**, H374-381, doi:
19 10.1152/ajpheart.01200.2009.
20
21
22

UU IR Author Manuscript

UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 **Table 1.** Morphology of 5 week old and 25 week old mice

2	**Con**	**G4H$^{-/-}$**
3 *4 week old (n)*	*7*	*7*
4 Body weight (g)	16.4±1.0	14.1±1.1
5 Heart weight (mg)	100±6	102±7
6 Tibia length (mm)	15.34±0.26	14.65±0.46
7 Heart : tibia (mg : mm)	6.51±0.31	6.94±0.36
8 GSSG	13.2±1.4	20.0±2.8*
9 GSH	798±38	887±44
10 GSH:GSSG	62.0±5.8	45.5± 3.9*
11 *25 week old (n)*	*11*	*11*
12 Body weight (g)	28.7±1.6	27.8±1.7
13 Heart weight (mg)	145±8	202±16*
14 Tibia length (mm)	18.1±0.1	18.2±0.2
15 Heart : tibia (mg : mm)	8.01±0.4	11.1±0.9*

16 Data are mean ± SEM. Adult mice aged 4.9±0.5 and 25±3 weeks old. * Indicates
17 significant differences at $p<0.05$. GSH and GSSG concentrations in 25-week-old cohort
18 are shown in Figure 1.
19

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

1 **Table 2.** Tempol (1 mM) treated mice

2	Con	G4H$^{-/-}$	Con + T	G4H$^{-/-}$ + T
3 *n*	*15*	*13*	*16*	*16*
4 Body weight (g)	20.5±0.8	22.3±0.8	20.9±0.7	19.4±0.7
5 Heart weight (mg)	110±4	146±5 *	110±4	121±6
6 Tibia length (mm)	17.2±0.2	17.2±0.1	17.0±0.1	16.7±0.2
7 Heart : tibia (mg : mm)	6.40±0.23	8.43±0.40 *	6.46±0.24	7.27±0.36
8 *Whole homogenate glutathione concentrations (nmol / g tissue)*				
9 *n*	*7*	*7*	*7*	*8*
10 GSH	799±34	634±36 *	604±27 *	598±31 *
11 GSSG	11.1±1.6	13.5±1.0	9.9±2.6	12.7±2.0
12 GSH:GSSG [a]	77±7	49±6	82±16	52±6

13

14 Data are mean ± SEM. GSH, reduced glutathione. GSSG, oxidized glutathione. Con (Control),
15 G4H$^{-/-}$ (Cardiac specific GLUT4 deletion), T = tempol. Mice were treated for 4 weeks, starting at
16 age 4-weeks and studied at the age of 8±0 weeks. * Significant differences at $p<0.05$ vs. Con.
17 [a] Main effects detected at $p<0.05$ for genotype (G4H$^{-/-}$ vs. Con), but interactions were not
18 significant.

UU IR Author Manuscript
UU IR Author Manuscript

INSTITUTIONAL REPOSITORY
THE UNIVERSITY OF UTAH
University of Utah Institutional Repository
Author Manuscript

Table 3. MnTBAP (2 mg / kg) treated mice

	Con	**$G4H^{-/-}$**	**Con+MnTBAP**	**$G4H^{-/-}$+MnTBAP**
n	*26*	*23*	*30*	*28*
Body weight (g)	21.2±0.6	20.4±0.6	21.3±0.5	21.0±0.5
Heart weight (mg)	110±3	135±4 *	111±3 133±3 *	
n	*17*	*17*	*19*	*22*
Tibia length (mm)	16.5±0.1	16.7±0.1	16.6±0.1	16.4±0.1
Heart : tibia (mg : mm)	6.74±0.23	8.22±0.23 *	6.73±0.22	7.99±0.20 *
Mitochondrial glutathione concentrations (nmol / mg mitochondrial protein)				
n	*10*	*12*	*14*	*11*
GSH	712±36	604±40	730±34	646±38
GSSG	19±3	34±3 *	16±3	23±3
GSH:GSSG	40±3	22±4 *	48±3	31±4

Data are mean ± SEM. GSH, reduced glutathione. GSSG, oxidized glutathione. Mice were treated for 4 weeks, starting at age 4-weeks and studied at the age of 8±0 weeks. * Significant differences at $p<0.05$ vs. Con.

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

Table 4. Primer pairs used for RT-PCR of selected genes in heart.

Gene	Sequence (5' - 3')	Product size (bp)
BNP	GGATCTCCTGAAGGTGCTGT TTCTTTTGTGAGGCCTTGGT	205
SERCA2a	GAAACTACCTGGAACAACCCG CTTTTCCCCAACCTCAGTCA	138
SERCA2b	GAAACTACCTGGAACAACCCG CGACAGGGAGCAGGAAGAT	65
α-MHC	ACTGTGGTGCCTCGTTCC TTCCGTTTTCAGTTTCCGC	276
β-MHC	CATTCTCCTGCTGTTTCCTTAC CATGGCTGAGCCTTGGAT	140
ANF	ATGGGCTCCTTCTCCATCA CCTGCTTCCTCAGTCTGCTC	209
GLUT1	GCGGGAGACGCATAGTTACA CTCCCACAGCCAACATGAG	130
GPX1	GACTGGTGGTGCTCGGTT TCACCATTCACTTCGCACTT	151
GPX4	GCAGGAGCCAGGAAGTAATCAAGA GCATCGTCCCCATTTACACA	99
GR	GTGGCACTTGCGTGAATGTTG GCACTGCTGTGTTCCACATTACCTT	60
TXN2	GTGTGGGCTTCCCTCACCTCT GGCTGGGCTGGGCATTACTGTTAGA	81
$p47^{phox}$	CCTGATGACCTGAAACTGCCCA GGTTGCCACGGTCATCTCTGTT	174
$p67^{phox}$	GACTATCTGGGCAAGGCTACGGTT AGGGGCGAAGCCAGAAAAGTTG	69
Cyclophilin	AGCACTGGAGAGAAAGGATTTGG TCTTCTTGCTGGTCTTGCCATT	349

UU IR Author Manuscript
UU IR Author Manuscript

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 **Figure legends**

2 **Figure 1.** Indices of oxidative stress in whole homogenates and isolated mitochondria
3 from hearts of cardiac specific GLUT4 deleted ($G4H^{-/-}$) and control (Con) mice. All mice
4 were 25±1 weeks old, except as indicated. **A)** Dichlorodihydrofluorescein diacetate
5 (DCFDA) assay (nmol dichlorodihydrofluorescein (DCF) / mg protein/min), from mice 8.0
6 ±0.5 weeks old, $G4H^{-/-}$; n= 8, Con; n=8. **B)** Mitochondrial hydrogen peroxide production
7 (μmol / L / min / mg mitochondrial protein), $G4H^{-/-}$; n= 6, Con; n=6. **C)** Malondialdehyde
8 content (nmol / g heart), $G4H^{-/-}$; n= 9, Con; n=7. **D)** Mitochondrial aconitase activity (nmol
9 aconitase used / min / mg mitochondrial protein), $G4H^{-/-}$; n= 6, Con; n=8. **E)** Cytosolic
10 aconitase activity (nmol aconitase used / min / mg protein), $G4H^{-/-}$; n= 9, Con; n=7. **F)**
11 Reduced (GSH) glutathione (nmol / g heart), $G4H^{-/-}$; n= 11, Con; n=10. **G)** Oxidized
12 (GSSG) glutathione (nmol / g heart), $G4H^{-/-}$; n= 11, Con; n=10. **H)** GSH : GSSG, $G4H^{-/-}$;
13 n= 11, Con; n=10. Data are mean ± SEM. * Indicates significant differences at $p<0.05$.

14 **Figure 2a, b,** mRNA levels as determined by quantitative PCR in hearts of cardiac
15 specific GLUT4 deleted ($G4H^{-/-}$, n=7), control (Con, n=8), tempol treated $G4H^{-/-}$ (+T, n=8,
16 1mM), and tempol treated Con mice (+T, n=9, 1mM). **2c,** mRNA levels as determined by
17 quantitative PCR in hearts of $G4H^{-/-}$ and Con mice treated with (Mn(III)tetrakis(4-Benzoic
18 acid) porphyrin Chloride (+MnTBAP, 10 mg/kg, ip) or Vehicle (+Veh, saline), n=4 for
19 each group. All samples are normalized to cyclophilin expression and normalized to
20 controls. Data are mean ± SEM. * Indicates significant differences at $p<0.05$. vs. Con.

21 **Figure 3a.** Glutathione peroxidase 4 (GPX4) and glutathione reductase (GR) protein
22 levels in hearts of cardiac specific GLUT4 deleted ($G4H^{-/-}$, n=7), control (Con, n=8) mice,
23 tempol treated $G4H^{-/-}$ (+T, n=8, 1mM), and tempol treated Con mice (+T, n=9, 1mM). **3b.**
24 GPX4 and GR protein levels in hearts of $G4H^{-/-}$ (n=4) and Con (n=3) mice treated with

University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript

UU IR Author Manuscript

1 (Mn(III)tetrakis(4-Benzoic acid) porphyrin Chloride (+MnTBAP, 10 mg/kg, ip, n=5) or
2 Vehicle (+Veh, saline, n=4). Data are mean ± SEM. * Indicates significant differences at
3 $p<0.05$. vs. Con.

4 **Figure 4.** p67^{phox} protein levels in membrane fractions of cardiac homogenates from
5 cardiac specific GLUT4 deleted (G4H$^{-/-}$, n=7), control (Con, n=7) mice, tempol treated
6 G4H$^{-/-}$ (+T, n=8, 1mM), and tempol treated Con mice (+T, n=7, 1mM). IR, insulin
7 receptor, used as loading control for membrane bound proteins. Data are mean ± SEM. *
8 Indicates significant differences at $p<0.05$ vs. Con.

9 **Figure 5.** Glycogen synthase kinase 3β (GSK) and phospho (p)-GSK3 β protein levels
10 in hearts of cardiac specific GLUT4 deleted (G4H$^{-/-}$, n=7), control (Con, n=8) mice,
11 tempol treated G4H$^{-/-}$ (+T, n=8, 1mM), and tempol treated Con mice (+T, n=9, 1mM).
12 Data are mean ± SEM.

13

Figure 1



Figure 2



University of Utah Institutional Repository
Author Manuscript

UU IR Author Manuscript



UU IR Author Manuscript

Figure 3





Figure 4





Figure 5.